Cargando…
Cardiovascular Impairment in COVID-19: Learning From Current Options for Cardiovascular Anti-Inflammatory Therapy
In December 2019, Coronavirus Disease 2019 (COVID-19) caused by SARS-CoV-2, occurred in China and has currently led to a global pandemic. In addition to respiratory involvement, COVID-19 was also associated with significant multiple organ dysfunction syndrome (MODS). Cardiovascular impairment has be...
Autores principales: | Wang, Lun, Zhang, Yang, Zhang, Shuyang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7203508/ https://www.ncbi.nlm.nih.gov/pubmed/32426374 http://dx.doi.org/10.3389/fcvm.2020.00078 |
Ejemplares similares
-
Anti-inflammatory Nanomedicine for Cardiovascular Disease
por: Katsuki, Shunsuke, et al.
Publicado: (2017) -
Anti-cancer Therapy Leads to Increased Cardiovascular Susceptibility to COVID-19
por: Lozahic, Caroline, et al.
Publicado: (2021) -
Editorial: What do we know about COVID-19 implications for cardiovascular disease?
por: Wang, Zeyuan, et al.
Publicado: (2023) -
Current progress of ferroptosis in cardiovascular diseases
por: Zhang, Jie, et al.
Publicado: (2023) -
Cardiovascular Complications of COVID-19 Vaccines
por: Liu, Runyu, et al.
Publicado: (2022)